The studies will be supported by Grant Number RC1-AI-081297, funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA). The award was made using authorities granted to the NIH by the Project BioShield Act of 2004. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, BARDA, or the NIH.
About Parion Sciences
Based in Durham, NC, Parion Sciences is a privately-held, development-stage pharmaceutical company that is leveraging its proprietary small molecule chemistry and epithelial biology expertise to discover and develop an innovative pipeline of therapies for diseases resulting from the failure of the body's mucosal defenses, including chronic obstructive pulmonary disorder (COPD), cystic fibrosis, bronchiactesis and Sjogren's syndrome. Parion's lead product candidate, CF-552, is currently in Phase II clinical development for the treatment dry mouth associated with Sjogren's syndrome. The company is also collaborating with Gilead Sciences on the development of drug candidates for pulmonary diseases. For more information, please visit www.parion.com.
About Lovelace Respiratory Research Institute
Lovelace Respiratory Research Institute is a not-for-profit research
institution founded in 1947 by Dr. William Randolph Lovelace II. It is one of
the nation's largest independent research institutions and the only one
focused solely on respiratory health. Scientists at LRRI are committed to
eradicating respiratory diseases through research aimed at understanding their
causes and biological mechanisms, eliminating exposures to causal agents, and
|SOURCE Parion Sciences|
Copyright©2008 PR Newswire.
All rights reserved